Suppr超能文献

一名患有杂合子因子V莱顿突变和共存纯合子凝血酶原基因突变患者的抗凝治疗

Anticoagulation Therapy in a Patient With Heterozygous Factor V Leiden and Coexisting Homozygous Prothrombin Gene Mutations.

作者信息

Costa Ryder L, Triggs Molly, Cole Shelbie E, Lacey Joshua, Reddy Samarth

机构信息

Research, Alabama College of Osteopathic Medicine, Dothan, USA.

Hematology and Oncology, Hematology Oncology Associates of Boca Raton, Boca Raton, USA.

出版信息

Cureus. 2020 Dec 7;12(12):e11949. doi: 10.7759/cureus.11949.

Abstract

Coexistent heterozygous factor V Leiden and homozygous prothrombin G20210A gene mutations is a rare and potentially life-threatening occurrence. This inherited thrombophilia often presents as non-specific venous thromboemboli and can mimic a variety of emergent medical conditions. The pathophysiology of the disease has been well documented; however, long-term treatment efficacy remains poorly understood. We report the case of a 25-year-old male presenting with acute chest pain. A comprehensive workup revealed bilateral pulmonary emboli arising in part from concomitant heterozygous factor V Leiden and homozygous prothrombin G20210A gene mutations. Immediate and continuous treatment with anticoagulants enoxaparin and apixaban significantly reduced the patient's symptoms and D-dimer within one week. This case provides insight into an effective treatment regimen for this rare and inherited thrombophilia.

摘要

并存的杂合子因子V莱顿突变和纯合子凝血酶原G20210A基因突变是一种罕见且可能危及生命的情况。这种遗传性易栓症常表现为非特异性静脉血栓栓塞,可类似多种紧急医疗状况。该疾病的病理生理学已有充分记录;然而,长期治疗效果仍知之甚少。我们报告一例25岁男性出现急性胸痛的病例。全面检查发现双侧肺栓塞部分源于并存的杂合子因子V莱顿突变和纯合子凝血酶原G20210A基因突变。使用抗凝剂依诺肝素和阿哌沙班进行即刻和持续治疗在一周内显著减轻了患者症状并降低了D-二聚体水平。该病例为这种罕见的遗传性易栓症的有效治疗方案提供了见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f62/7785497/7afe9546b7b3/cureus-0012-00000011949-i01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验